These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 10704105)

  • 41. Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors.
    Wang X; Furukawa T; Nitanda T; Okamoto M; Sugimoto Y; Akiyama S; Baba M
    Mol Pharmacol; 2003 Jan; 63(1):65-72. PubMed ID: 12488537
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nevirapine and delavirdine plus protease inhibitors.
    GMHC Treat Issues; 1996 Apr; 10(4):8. PubMed ID: 11363709
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Chalcogenozidovudine Derivatives With Antitumor Activity: Comparative Toxicities in Cultured Human Mononuclear Cells.
    Ecker A; Ledur PC; da Silva RS; Leal DBR; Rodrigues OED; Ardisson-Araújo D; Waczuk EP; da Rocha JBT; Barbosa NV
    Toxicol Sci; 2017 Nov; 160(1):30-46. PubMed ID: 29036705
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Quantification of darunavir and etravirine in human peripheral blood mononuclear cells using high performance liquid chromatography tandem mass spectrometry (LC-MS/MS), clinical application in a cohort of 110 HIV-1 infected patients and evidence of a potential drug-drug interaction.
    Belkhir L; De Laveleye M; Vandercam B; Zech F; Delongie KA; Capron A; Yombi J; Vincent A; Elens L; Haufroid V
    Clin Biochem; 2016 May; 49(7-8):580-6. PubMed ID: 26742721
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tacrolimus diffusion across the peripheral mononuclear blood cell membrane: impact of drug transporters.
    Tron C; Allard M; Petitcollin A; Ferrand-Sorre MJ; Verdier MC; Querzerho-Raguideau J; Blanchet B; Le Priol J; Roussel M; Deugnier Y; Bellissant E; Lemaitre F
    Fundam Clin Pharmacol; 2019 Feb; 33(1):113-121. PubMed ID: 30203853
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug.
    Wire MB; Shelton MJ; Studenberg S
    Clin Pharmacokinet; 2006; 45(2):137-68. PubMed ID: 16485915
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Structure-based design of sulfonamide-substituted non-peptidic HIV protease inhibitors.
    Skulnick HI; Johnson PD; Howe WJ; Tomich PK; Chong KT; Watenpaugh KD; Janakiraman MN; Dolak LA; McGrath JP; Lynn JC
    J Med Chem; 1995 Dec; 38(26):4968-71. PubMed ID: 8544171
    [No Abstract]   [Full Text] [Related]  

  • 48. Protein binding in antiretroviral therapies.
    Boffito M; Back DJ; Blaschke TF; Rowland M; Bertz RJ; Gerber JG; Miller V
    AIDS Res Hum Retroviruses; 2003 Sep; 19(9):825-35. PubMed ID: 14585213
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacology of antiretroviral drugs.
    Hoetelmans RM
    Antivir Ther; 1999; 4 Suppl 3():29-41. PubMed ID: 16021869
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Enhancement of zidovudine uptake by dehydroepiandrosterone sulfate in rat syncytiotrophoblast cell line TR-TBT 18d-1.
    Nishimura T; Seki Y; Sato K; Chishu T; Kose N; Terasaki T; Kang YS; Sai Y; Nakashima E
    Drug Metab Dispos; 2008 Oct; 36(10):2080-5. PubMed ID: 18653745
    [TBL] [Abstract][Full Text] [Related]  

  • 51. APHS can act synergically with clinically available HIV-1 reverse transcriptase and protease inhibitors and is active against several drug-resistant HIV-1 strains in vitro.
    Pereira CF; Paridaen JT; van de Bovenkamp M; Middel J; Verhoef J; Nottet HS
    J Antimicrob Chemother; 2003 May; 51(5):1181-9. PubMed ID: 12668583
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Concentrations of zidovudine- and lamivudine-triphosphate according to cell type in HIV-seronegative adults.
    Anderson PL; Zheng JH; King T; Bushman LR; Predhomme J; Meditz A; Gerber J; Fletcher CV
    AIDS; 2007 Sep; 21(14):1849-54. PubMed ID: 17721092
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Drug-antibody conjugates with anti-HIV activity.
    Paulik M; Grieco P; Kim C; Maxeiner HG; Grunert HP; Zeichhardt H; Morré DM; Morré DJ
    Biochem Pharmacol; 1999 Dec; 58(11):1781-90. PubMed ID: 10571253
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV.
    Hazen R; Harvey R; Ferris R; Craig C; Yates P; Griffin P; Miller J; Kaldor I; Ray J; Samano V; Furfine E; Spaltenstein A; Hale M; Tung R; St Clair M; Hanlon M; Boone L
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3147-54. PubMed ID: 17620375
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Differential effect of azidothymidine on resting and activated cells: potentiality of this drug for treatment of post-transfusion graft-versus-host disease.
    Nishimura M; Hidaka N; Akaza T; Tadokoro K; Juji T
    Res Commun Mol Pathol Pharmacol; 1998 May; 100(2):131-8. PubMed ID: 9667067
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Concentration-controlled compared with conventional antiretroviral therapy for HIV infection.
    Fletcher CV; Anderson PL; Kakuda TN; Schacker TW; Henry K; Gross CR; Brundage RC
    AIDS; 2002 Mar; 16(4):551-60. PubMed ID: 11872998
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Yang S; Pannecouque C; Daelemans D; Ma XD; Liu Y; Chen FE; De Clercq E
    Eur J Med Chem; 2013 Jul; 65():134-43. PubMed ID: 23707918
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evidence and possible consequences of the phosphorylation of nucleoside reverse transcriptase inhibitors in human red blood cells.
    Durand-Gasselin L; Da Silva D; Benech H; Pruvost A; Grassi J
    Antimicrob Agents Chemother; 2007 Jun; 51(6):2105-11. PubMed ID: 17438052
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV- infected subjects: ACTG 884.
    Fletcher CV; Acosta EP; Cheng H; Haubrich R; Fischl M; Raasch R; Mills C; Hu XJ; Katzenstein D; Remmel RP; Gulick RM;
    AIDS; 2000 Nov; 14(16):2495-501. PubMed ID: 11101060
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Intracellular pharmacokinetics of antiretroviral agents.
    Owen A; Khoo SH
    J HIV Ther; 2004 Nov; 9(4):97-101. PubMed ID: 15731742
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.